RxSight, Inc. Reports Third Quarter 2024 Financial Results
RxSight reported strong Q3 2024 financial results with revenue of $35.3 million, up 59% year-over-year. The company sold 24,554 Light Adjustable Lenses (LAL™/LAL+™), an 80% increase, and 78 Light Delivery Devices (LDD™s), an 18% increase from Q3 2023. The installed base grew to 888 LDDs, up 51% year-over-year. Gross profit reached $25.2 million with a 71.4% margin. Despite operating expenses of $34.4 million, net loss improved to $(6.3) million. The company raised its 2024 full-year revenue guidance to $140 million, with improved gross margin guidance of 70-71% and lower operating expenses.
RxSight ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con ricavi pari a 35,3 milioni di dollari, in aumento del 59% rispetto all'anno precedente. L'azienda ha venduto 24.554 Lenti Regolabili con Luce (LAL™/LAL+™), un incremento dell'80%, e 78 Dispositivi di Consegna della Luce (LDD™s), con un aumento del 18% rispetto al terzo trimestre del 2023. La base installata è cresciuta a 888 LDD, con un aumento del 51% su base annua. Il profitto lordo ha raggiunto i 25,2 milioni di dollari, con un margine del 71,4%. Nonostante le spese operative di 34,4 milioni di dollari, la perdita netta è migliorata a $(6,3) milioni. L'azienda ha alzato la sua previsione di ricavi per l'intero anno 2024 a 140 milioni di dollari, con una previsione di margine lordo migliorata del 70-71% e spese operative ridotte.
RxSight reportó resultados financieros sólidos en el tercer trimestre de 2024, con ingresos de $35.3 millones, un aumento del 59% interanual. La compañía vendió 24,554 Lentes Ajustables a Luz (LAL™/LAL+™), un incremento del 80%, y 78 Dispositivos de Entrega de Luz (LDD™s), un aumento del 18% respecto al tercer trimestre de 2023. La base instalada creció a 888 LDD, un aumento del 51% interanual. El beneficio bruto alcanzó los $25.2 millones con un margen del 71.4%. A pesar de los gastos operativos de $34.4 millones, la pérdida neta mejoró a $(6.3) millones. La compañía elevó su guía de ingresos para todo el año 2024 a $140 millones, con una mejora en la guía de márgenes brutos del 70-71% y menores gastos operativos.
RxSight는 2024년 3분기 재무 성과가 강력하다고 보고했으며, 수익은 $35.3 백만으로 전년 대비 59% 증가했습니다. 회사는 24,554개의 조정 가능한 빛 렌즈(LAL™/LAL+™)를 판매했으며, 이는 80% 증가했고 78개의 빛 전달 장치(LDD™)를 판매했으며 이는 2023년 3분기 대비 18% 증가했습니다. 설치된 기반은 888개의 LDD로 증가했으며, 이는 전년 대비 51% 증가한 것입니다. 총 이익은 $25.2 백만에 도달했으며, 이는 71.4%의 마진을 나타냅니다. 운영 비용이 $34.4 백만에 달했음에도 불구하고, 순손실은 $(6.3) 백만으로 개선되었습니다. 회사는 2024년 전체 연도 수익 가이드를 $140 백만으로 상향 조정하였으며, 개선된 총 마진 가이드는 70-71%로, 운영 비용은 감소할 것으로 예상하고 있습니다.
RxSight a rapporté de solides résultats financiers pour le troisième trimestre 2024, avec des revenus de 35,3 millions de dollars, en hausse de 59 % par rapport à l'année précédente. L'entreprise a vendu 24 554 Lentilles Ajustables à Lumière (LAL™/LAL+™), soit une augmentation de 80 %, et 78 Dispositifs de Livraison de Lumière (LDD™s), soit une augmentation de 18 % par rapport au troisième trimestre 2023. La base installée a augmenté pour atteindre 888 LDD, ce qui représente une augmentation de 51 % par rapport à l'année précédente. Le bénéfice brut a atteint 25,2 millions de dollars avec une marge de 71,4 %. Malgré des dépenses d'exploitation de 34,4 millions de dollars, la perte nette s'est améliorée pour atteindre $(6,3) millions. L'entreprise a relevé ses prévisions de revenus pour l'année 2024 à 140 millions de dollars, avec une prévision de marge brute améliorée de 70-71 % et des dépenses d'exploitation réduites.
RxSight berichtete über starke finanzielle Ergebnisse für das dritte Quartal 2024 mit einem Umsatz von 35,3 Millionen Dollar, was einem Anstieg von 59 % im Vergleich zum Vorjahr entspricht. Das Unternehmen verkaufte 24.554 Lichtverstellbare Linsen (LAL™/LAL+™), was einem Anstieg von 80 % entspricht, und 78 Lichtabgabegeräte (LDD™s), was einem Anstieg von 18 % im Vergleich zum dritten Quartal 2023 entspricht. Der installierte Bestand wuchs auf 888 LDDs, was einem Anstieg von 51 % im Jahresvergleich entspricht. Der Bruttogewinn erreichte 25,2 Millionen Dollar bei einer Marge von 71,4 %. Trotz Betriebsausgaben von 34,4 Millionen Dollar verbesserte sich der Nettoverlust auf $(6,3) Millionen. Das Unternehmen hob seine Umsatzprognose für das Jahr 2024 auf 140 Millionen Dollar an, mit einer verbesserten Bruttomargenprognose von 70 – 71 % und geringeren Betriebskosten.
- Revenue grew 59% YoY to $35.3 million
- LAL sales volume increased 80% YoY
- Gross profit margin improved to 71.4% from 61.9% YoY
- Installed base expanded 51% YoY to 888 LDDs
- Net loss improved from $(12.4M) to $(6.3M) YoY
- Raised full-year revenue guidance to $140M
- Operating expenses increased 31% YoY to $34.4 million
- Continued net loss of $(6.3) million in Q3 2024
Insights
RxSight delivered exceptional Q3 results with
The transition to adjusted profitability (
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024.
Key Quarterly Highlights
- Reported third quarter 2024 revenue of
$35.3 million , an increase of59% compared to the third quarter of 2023, reflecting:- The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an
80% increase in procedure volume compared to the third quarter of 2023; and - The sale of 78 Light Delivery Devices (LDD™s), representing a
18% increase in unit sales compared to the third quarter of 2023 and expanding the installed base to 888 LDDs at the end of the quarter, representing a51% increase compared to the end of the third quarter of 2023.
- The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an
- The company raised its 2024 full-year revenue guidance to the top of its previous guidance range, increased its gross margin guidance and lowered its operating expense guidance.
“We are pleased to report another strong quarter driven by ongoing demand and enthusiasm for the RxSight system,” said Dr. Ron Kurtz, Chief Executive Officer and President. “With 78 LDDs sold this quarter and sustained growth in LAL sales, we continue to see recognition of the transformative power of adjustability and the significant value it provides to both patients and doctors. We believe our third-quarter results position us for a strong finish to 2024 and for continued success in the years to come.”
Third Quarter Financial Results
In the third quarter of 2024, total revenue was
Gross profit for the third quarter of 2024 was
Total operating expenses for the third quarter of 2024 were
In the third quarter of 2024, the company reported a net loss of
Cash, cash equivalents and short-term investments as of September 30, 2024, were
2024 Guidance
The company revised its 2024 full-year revenue, gross margin and operating expense guidance as follows:
- Revenue at the top of previously provided guidance range of
$139.0 million to$140.0 million , representing implied growth of approximately57% compared to 2023; - Gross margin in the range of
70% to71% , up from previous guidance range of68% to70% ; and - Operating expenses at the low end of its previously provided guidance range of
$135.0 t o$136.0 million , including non-cash stock-based compensation expense, now also expected at the lower end of the previous guidance range of$29.0 t o$30.0 million .
Conference Call
On Thursday, November 7, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its third quarter 2024 financial results. To participate in the conference call, please dial
(888) 596-4144 or (646) 968-2525 and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: management’s views regarding the transformative power of adjustability and the significant value it provides to both patients and doctors; management’s belief that RxSight is positioned for a strong finish to 2024 and for continued success in the years to come; and RxSight’s revised projected revenue, gross margin, and operating expenses for 2024. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
| RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Sales | $ | 35,314 | $ | 22,199 | $ | 99,713 | $ | 60,497 | ||||||||
| Cost of sales | 10,094 | 8,468 | 29,558 | 24,386 | ||||||||||||
| Gross profit | 25,220 | 13,731 | 70,155 | 36,111 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 25,608 | 19,142 | 73,225 | 53,634 | ||||||||||||
| Research and development | 8,838 | 7,101 | 25,160 | 21,710 | ||||||||||||
| Total operating expenses | 34,446 | 26,243 | 98,385 | 75,344 | ||||||||||||
| Loss from operations | (9,226 | ) | (12,512 | ) | (28,230 | ) | (39,233 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest expense | (5 | ) | (230 | ) | (16 | ) | (3,304 | ) | ||||||||
| Interest and other income | 2,906 | 1,746 | 6,767 | 4,913 | ||||||||||||
| Loss on extinguishment of term loan | — | (1,407 | ) | — | (1,769 | ) | ||||||||||
| Loss before income taxes | (6,325 | ) | (12,403 | ) | (21,479 | ) | (39,393 | ) | ||||||||
| Income tax expense | 13 | 12 | 38 | 38 | ||||||||||||
| Net loss | $ | (6,338 | ) | $ | (12,415 | ) | $ | (21,517 | ) | $ | (39,431 | ) | ||||
| Other comprehensive (loss) income | ||||||||||||||||
| Unrealized gain on short-term investments | 633 | 19 | 524 | 38 | ||||||||||||
| Foreign currency translation gain (loss) | 6 | (6 | ) | 2 | (3 | ) | ||||||||||
| Total other comprehensive income | 639 | 13 | 526 | 35 | ||||||||||||
| Comprehensive loss | $ | (5,699 | ) | $ | (12,402 | ) | $ | (20,991 | ) | $ | (39,396 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic & diluted | $ | (0.16 | ) | $ | (0.35 | ) | $ | (0.56 | ) | $ | (1.16 | ) | ||||
| Weighted-average shares used in computing net loss per share: | ||||||||||||||||
| Attributable to common stock, basic & diluted | 39,788,621 | 35,662,397 | 38,367,759 | 33,947,331 | ||||||||||||
| RxSIGHT, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) | ||||||||
| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 16,720 | $ | 9,692 | ||||
| Short-term investments | 220,400 | 117,490 | ||||||
| Accounts receivable, net | 25,368 | 20,281 | ||||||
| Inventories, net | 21,673 | 17,421 | ||||||
| Prepaid and other current assets | 2,607 | 3,523 | ||||||
| Total current assets | 286,768 | 168,407 | ||||||
| Property and equipment, net | 12,241 | 10,841 | ||||||
| Operating leases right-of-use assets | 10,536 | 2,444 | ||||||
| Restricted cash | 711 | 711 | ||||||
| Other assets | 213 | 147 | ||||||
| Total assets | $ | 310,469 | $ | 182,550 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,581 | $ | 3,863 | ||||
| Accrued expenses and other current liabilities | 17,323 | 15,239 | ||||||
| Lease liabilities | 734 | 1,801 | ||||||
| Total current liabilities | 22,638 | 20,903 | ||||||
| Long-term lease liabilities | 10,570 | 1,211 | ||||||
| Other long-term liabilities | — | 74 | ||||||
| Total liabilities | 33,208 | 22,188 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, 40,254,105 shares issued and outstanding as of September 30, 2024 and 36,139,513 shares issued and outstanding as of December 31, 2023 | 40 | 36 | ||||||
| Preferred stock, and outstanding | — | — | ||||||
| Additional paid-in capital | 892,857 | 754,971 | ||||||
| Accumulated other comprehensive income (loss) | 521 | (5 | ) | |||||
| Accumulated deficit | (616,157 | ) | (594,640 | ) | ||||
| Total stockholders' equity | 277,261 | 160,362 | ||||||
| Total liabilities and stockholders' equity | $ | 310,469 | $ | 182,550 | ||||
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and loss on extinguishment of debt because these expenses are non-cash in nature and we believe excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for (i) stock-based compensation and (ii) loss on extinguishment of term loan. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
| RxSIGHT, INC. GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED) (In thousands, except share and per share amounts) | ||||||||||||||||
| Three months ended September 30, | For the nine months ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Common Stock | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss available to stockholders, basic and diluted | $ | (6,338 | ) | $ | (12,415 | ) | $ | (21,517 | ) | $ | (39,431 | ) | ||||
| Add: | ||||||||||||||||
| Stock-based compensation | 6,552 | 4,071 | 17,353 | 11,321 | ||||||||||||
| Loss on extinguishment of term loan | — | 1,407 | — | 1,769 | ||||||||||||
| Adjusted net income (loss) available to common stockholders, basic and diluted: | $ | 214 | $ | (6,937 | ) | $ | (4,164 | ) | $ | (26,341 | ) | |||||
| Denominator: | ||||||||||||||||
| Weighted-average shares outstanding, basic | 39,788,621 | 35,662,397 | 38,367,759 | 33,947,331 | ||||||||||||
| Weighted-average shares outstanding, diluted | 45,748,177 | 35,662,397 | 38,367,759 | 33,947,331 | ||||||||||||
| Adjusted net earnings (loss) per share, basic | $ | 0.01 | $ | (0.19 | ) | $ | (0.11 | ) | $ | (0.78 | ) | |||||
| Adjusted net earnings (loss) per share, diluted | $ | 0.00 | $ | (0.19 | ) | $ | (0.11 | ) | $ | (0.78 | ) | |||||
FAQ
What was RxSight's (RXST) revenue growth in Q3 2024?
How many Light Adjustable Lenses did RxSight (RXST) sell in Q3 2024?
What is RxSight's (RXST) updated revenue guidance for 2024?
What was RxSight's (RXST) gross margin in Q3 2024?
